C4 Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of C4 Therapeutics generated cash of -$106,838,000, which is less than the previous year. Cash used in financing activities reached the amount of $45,489,000 last year. Net change in cash is therefore $97,000,000.
Cash Flow
| 2018 | -16.98M | 36.92M | 1.96M |
|---|---|---|---|
| 2019 | 55.61M | -1.62M | 244K |
| 2020 | -67.24M | -190.50M | 348.93M |
| 2021 | -86.96M | -189.33M | 171.4M |
| 2022 | -105.93M | 58.42M | 1.14M |
| 2023 | -106.83M | 158.34M | 45.48M |
CCCC Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 33.03M | 79.40M | 184.30M | 93.12M | 38.88M | 16.98M |
Operating activities | ||||||
Net income | -132.49M | -128.17M | -83.89M | -66.33M | -34.09M | -15.71M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 1.88M | 1.67M | 1.49M | 1.61M | 1.59M | 1.27M |
Stock-based compensation expense | 27.23M | 30.01M | 21.51M | 3.43M | 1.64M | 0 |
| Deferred income tax benefit | 27.23M | 30.01M | 21.51M | 3.43M | 1.64M | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -10.32M | 4.24M | -1.23M | 139K | 81.81M | -84.94M |
Inventories | 0 | 0 | -2.62M | -1.58M | 2.17M | -2.22M |
Accounts payable | 273K | -3.33M | -1.17M | 467K | 4.23M | 578K |
Cash generated by operating activities | -106.83M | -105.93M | -86.96M | -67.24M | 55.61M | -16.98M |
Investing activities | ||||||
Purchases Of Investments | -129.89M | -219.52M | -537.74M | -293.85M | -79M | -4.99M |
Investments In Property Plant And Equipment | -1.70M | -5.49M | -1.27M | -650K | -1.34M | -2.68M |
Acquisitions Net | 0 | -63.91M | 188.05M | 189.85M | 63K | 0 |
Cash generated by investing activities | 158.34M | 58.42M | -189.33M | -190.50M | -1.62M | 36.92M |
Financing activities | ||||||
Common Stock Issued | 57.67M | 777K | 169.46M | 340.59M | 0 | 47K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -110K | 0 | 0 | -194K | -30K | 0 |
Repayments of term debt | -12.5M | 0 | 0 | -11.97M | 0 | 0 |
Cash used in financing activities | 45.48M | 1.14M | 171.4M | 348.93M | 244K | 1.96M |
Net Change In Cash | 97M | -46.37M | -104.90M | 91.17M | 54.23M | 21.90M |
Cash at end of period | 130.03M | 33.03M | 79.40M | 184.30M | 93.12M | 38.88M |
| Data source | Data source | Data source | Data source |